

Onconova Therapeutics, Inc.
Form 4
August 01, 2013

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
Hoffman Michael B

2. Issuer Name and Ticker or Trading Symbol
Onconova Therapeutics, Inc.
[ONTX]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)
07/30/2013

Director 10% Owner
 Officer (give title below) Other (specify below)

712 FIFTH AVENUE, 36TH FLOOR

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

NEW YORK, NY 10019

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
				(A) or (D)	Price				
				Code	V	Amount			
Common Stock	07/30/2013		C	83,857	A	①	728,517	I	By The Michael and Jane Hoffman 2013 Descendants Trust ⁽⁹⁾
Common Stock	07/30/2013		C	105,363	A	②	833,880	I	By The Michael and Jane Hoffman

Edgar Filing: Onconova Therapeutics, Inc. - Form 4

Common Stock	07/30/2013	C	266,712	A	<u>(3)</u>	1,100,592	I	2013 Descendants Trust <u>(9)</u> By The Michael and Jane Hoffman 2013 Descendants Trust <u>(9)</u>
Common Stock	07/30/2013	C	476,087	A	<u>(4)</u>	1,576,679	I	By The Michael and Jane Hoffman 2013 Descendants Trust <u>(9)</u>
Common Stock	07/30/2013	C	85,744	A	<u>(5)</u>	1,662,423	I	By The Michael and Jane Hoffman 2013 Descendants Trust <u>(9)</u>
Common Stock	07/30/2013	C	84,530	A	<u>(5)</u>	1,746,953	I	By The Michael and Jane Hoffman 2013 Descendants Trust (Non-GST Exempt Trust) <u>(9)</u>
Common Stock	07/30/2013	C	172,411	A	<u>(6)</u>	1,919,364	I	By The Michael and Jane Hoffman 2013 Descendants Trust <u>(9)</u>
Common Stock	07/30/2013	C	226,024	A	<u>(7)</u>	2,145,388	I	By The Michael and Jane Hoffman 2013 Descendants

Edgar Filing: Onconova Therapeutics, Inc. - Form 4

Common Stock	07/30/2013	C	1,226,942	A	<u>(8)</u>	3,372,330	I	Trust ⁽⁹⁾ By The Michael and Jane Hoffman 2013 Descendants Trust ⁽⁹⁾
Common Stock	07/30/2013	P	1,000,000	A	\$ 15	4,372,330	I	By The Michael and Jane Hoffman 2013 Descendants Trust ⁽⁹⁾

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	Amount
				Code	V (A) (D)	Date Exercisable Expiration Date	Title	Number Shares
Series B Convertible Preferred Stock	<u>(1)</u>	07/30/2013		C	99,350	<u>(1)</u> <u>(1)</u>	Common Stock	83,8
Series C Convertible Preferred Stock	<u>(2)</u>	07/30/2013		C	140,449	<u>(2)</u> <u>(2)</u>	Common Stock	105,3
	<u>(3)</u>	07/30/2013		C	355,528	<u>(3)</u> <u>(3)</u>		266,7

Edgar Filing: Onconova Therapeutics, Inc. - Form 4

Series D
Convertible
Preferred
Stock

Common
Stock

Series E
Convertible
Preferred
Stock

(4)

07/30/2013

C

634,625

(4)

(4)

Common
Stock

476,0

Series F
Convertible
Preferred
Stock

(5)

07/30/2013

C

111,227

(5)

(5)

Common
Stock

85,7

Series F
Convertible
Preferred
Stock

(5)

07/30/2013

C

109,653

(5)

(5)

Common
Stock

84,5

Series G
Convertible
Preferred
Stock

(6)

07/30/2013

C

229,825

(6)

(6)

Common
Stock

172,4

Series H
Convertible
Preferred
Stock

(7)

07/30/2013

C

301,290

(7)

(7)

Common
Stock

226,0

Series I
Convertible

(8)

07/30/2013

C

1,635,514

(8)

(8)

Common
Stock

1,226

Preferred
Stock

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Hoffman Michael B 712 FIFTH AVENUE, 36TH FLOOR NEW YORK, NY 10019	X	X		

Signatures

/s/ Ajay Bansal, as attorney
in fact

07/30/2013

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) The Series B Convertible Preferred Stock converted into Common Stock on a 0.85-for-1 basis and had no expiration date.
- (2) The Series C Convertible Preferred Stock converted into Common Stock on a 0.75-for-1 basis and had no expiration date.
- (3) The Series D Convertible Preferred Stock converted into Common Stock on a 0.75-for-1 basis and had no expiration date.
- (4) The Series E Convertible Preferred Stock converted into Common Stock on a 0.75-for-1 basis and had no expiration date.
- (5) The Series F Convertible Preferred Stock converted into Common Stock on a 0.77-for-1 basis and had no expiration date.
- (6) The Series G Convertible Preferred Stock converted into Common Stock on a 0.75-for-1 basis and had no expiration date.
- (7) The Series H Convertible Preferred Stock converted into Common Stock on a 0.75-for-1 basis and had no expiration date.
- (8) The Series I Convertible Preferred Stock converted into Common Stock on a 0.75-for-1 basis and had no expiration date.
- (9) These shares are held in a trust for the benefit of the reporting person's descendants. The reporting person's spouse is a trustee of the trust.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.